RxDoctor Payments DataLook up a doctor →

Thomas Smith, MD

Cardiovascular Disease · Sacramento, CANPI 1215955844

Payments from drug & device makers

$942,360in general payments, 2019–2025

Across 368 payments — averaging $2560.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$298K
  • Johnson & Johnson$277K
  • W. L. Gore & Associates, Inc.$210K
  • Boston Scientific$133K
  • Biosense Webster, Inc.$20K
  • Novo Nordisk AS$4K
  • plus $405 from 6 others

What the payments were for

  • Consulting fees$471,48750%
  • Speaking & faculty fees$4,2500%
  • Travel & lodging$86,2729%
  • Food & beverage$10,5351%
  • Ownership interest$92,45910%
  • Other$277,35729%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$942,360 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$110,720
Medicare patients
1,392
Services billed
2,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban137$204,025
EntrestoSacubitril/Valsartan23$26,026
JardianceEmpagliflozin12$19,968
BrilintaTicagrelor17$16,968
Clonidine19$3,817
Rosuvastatin Calcium124$2,244
Metoprolol Succinate124$2,203
Atorvastatin Calcium150$2,105
Valsartan28$1,500
Amlodipine Besylate142$1,144
Bisoprolol Fumarate20$1,101
Spironolactone59$1,031
Losartan Potassium88$989
Isosorbide Mononitrate ErIsosorbide Mononitrate37$873
Amiodarone Hcl15$776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$14$16,96817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →